Compounds targeting Foxp3, such as Trichostatin A, G9a inhibitors, and Resveratrol, aim to correct these epigenetic disruptions and restore Treg cell function, which could be pivotal in managing MS. The gene discussed is FOXP3; the disease is myeloid sarcoma.